Endüstriler
Showing 51–60 ile ilgili 134 results
-
Non-small-cell Lung Carcinoma (NSCLC) Market in China
At 3% CAGR, the non-small-cell lung carcinoma (NSCLC) market in China is projected to reach 967 thousand units by 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Nasopharyngeal Cancer Market in China
According to a statistic by StrategyHelix, the nasopharyngeal cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.2% in the next five years.
-
Head and Neck Cancer Market in China
The head and neck cancer market in China, in terms of volume, is expected to expand at a CAGR of 1.7% itibaren 2021 başından sonuna kadar 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Global Immuno-Oncology Therapy Market
The global immuno-oncology therapy market is expected to increase at a CAGR of 22.6% till 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Oncology Drug Market in China
The oncology drug market in China is poised to grow at a CAGR of around 13.3% analiz dönemi boyunca 2021 ile 2027, veri ve analiz şirketi StratejiHelix'e göre.
-
Global Oncology Drug Market
According to a statistic by StrategyHelix, the global oncology drug market is poised to grow at a CAGR of around 12.6% analiz dönemi boyunca 2021 ile 2027.
-
Biomedical Materials Market in China
A statistic by StrategyHelix indicates that the biomedical materials market in China is expected to increase at a CAGR of 11.5% till 2027.
-
Home Use Medical Device Market in China
The home use medical device market in China is set to increase by US$ 12,122 million from 2021 ile 2027, representing a compound annual growth rate (CAGR) ile ilgili 10% tahmin dönemi boyunca.
-
Blood Glucose Market in China
The blood glucose market in China is poised to grow by US$ 18,136 sırasında milyon 2021-2027, CAGR'da ilerliyor 22.8% tahmin dönemi boyunca, veri ve analiz şirketi StratejiHelix'e göre.
-
Nutritional Supplement Market in China
The nutritional supplement market in China was around 233 m units in 2020, reached 272 m units in 2021 (an increase of 16.5% year-on-year), according to StrategyHelix’ analiz.